Literature DB >> 15181453

Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors.

Muna Sabah1, Robert Cummins, Mary Leader, Elaine Kay.   

Abstract

Gastrointestinal stromal tumors GISTs are distinctive KIT-positive mesenchymal neoplasms. The genetic alterations leading to the malignant behavior of these tumors are not well characterized. In this study, 21 cases of GISTs (eight low malignant potential, nine primary malignant and four intra-abdominal recurrences) were characterized by immunohistochemistry and evaluated for loss of heterozygosity of the short arm of chromosome 9, using six microsatellite markers. Loss of heterozygosity with at least one microsatellite marker at 9p region was a common finding in high-risk GISTs (malignant and recurrent group) but was absent in the low malignant potential group. Recurrent GISTs showed more frequent deletions than their primary tumors. All cases with loss of heterozygosity showed deletions at 9p21. Similarly, all low malignant potential GISTs were immunoreactive for p16, whereas malignant tumors were negative for p16. These results suggest that loss of p16(INK4A) gene on 9p may contribute to the progression and/or malignant transformation of GISTs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181453     DOI: 10.1038/modpathol.3800199

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  13 in total

1.  Loss of chromosome 9p21 and decreased p16 expression correlate with malignant gastrointestinal stromal tumor.

Authors:  Yun Zhang; Hui Cao; Ming Wang; Wen-Yi Zhao; Zhi-Yong Shen; Dan-Ping Shen; Xing-Zhi Ni; Zhi-Yong Wu; Yan-Ying Shen; Yan-Yan Song
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

2.  Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis.

Authors:  Lorin E Olson; Philippe Soriano
Journal:  Dev Cell       Date:  2009-02       Impact factor: 12.270

3.  Presence of PDGFRA and DOG1 mutations in gastrointestinal stromal tumors among Chinese population.

Authors:  Jiehua Li; Haitian Zhang; Yunfei Lu; Zhibai Chen; Ka Su
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  Loss of p16INK4A expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected synovial sarcomas.

Authors:  Muna Sabah; Robert Cummins; Mary Leader; Elaine Kay
Journal:  Virchows Arch       Date:  2005-08-05       Impact factor: 4.064

5.  Leiomyosarcoma and malignant fibrous histiocytoma share similar allelic imbalance pattern at 9p.

Authors:  Muna Sabah; Robert Cummins; Mary Leader; Elaine Kay
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

Review 6.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

Review 7.  Gastrointestinal stromal tumors.

Authors:  Bernadette Liegl-Atzwanger; Jonathan A Fletcher; Christopher D M Fletcher
Journal:  Virchows Arch       Date:  2010-02-18       Impact factor: 4.064

8.  p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome.

Authors:  Michael Schmieder; Sebastian Wolf; Bettina Danner; Susanne Stoehr; Markus S Juchems; Peter Wuerl; Doris Henne-Bruns; Uwe Knippschild; Cornelia Hasel; Klaus Kramer
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

Review 9.  Genetic aberrations of gastrointestinal stromal tumors.

Authors:  Jilong Yang; Xiaoling Du; Alexander J F Lazar; Raphael Pollock; Kelly Hunt; Kexin Chen; Xishan Hao; Jonathan Trent; Wei Zhang
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  Two distinct pathways of p16 gene inactivation in gallbladder cancer.

Authors:  Hiroyuki Tadokoro; Takako Shigihara; Tomomi Ikeda; Masaru Takase; Masafumi Suyama
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.